<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PSA Rising Prostate Cancer Blog &#187; Hormone refractory</title>
	<atom:link href="http://www.psa-rising.com/blog/category/pca/hormone-refractory/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.psa-rising.com/blog</link>
	<description></description>
	<lastBuildDate>Wed, 25 Nov 2009 18:36:49 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.8.6</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>&#8220;Complete Remission&#8221; in Hormone Refractory Prostate Cancer</title>
		<link>http://www.psa-rising.com/blog/2007/06/complete-remission-in-hormone-refractory-prostate-cancer/</link>
		<comments>http://www.psa-rising.com/blog/2007/06/complete-remission-in-hormone-refractory-prostate-cancer/#comments</comments>
		<pubDate>Fri, 01 Jun 2007 22:43:38 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Clinical trials]]></category>
		<category><![CDATA[Hormone refractory]]></category>
		<category><![CDATA[Prostate Cancer]]></category>
		<category><![CDATA[capecitabine]]></category>
		<category><![CDATA[etoricoxib]]></category>

		<guid isPermaLink="false">http://psa-rising.com/blog/index.php/2007/06/01/complete-remission-in-hormone-refractory-prostate-cancer</guid>
		<description><![CDATA[From ASCO annual general meeting, 2007, comes this abstract of a study by A. Reichle, B. Walter, A. Berand, M. Vogelhuber, K. Bross, J. Wilke, W. Wieland, R. Andreesen, S. Rogenhofer.
Background: The present multi-centre phase II study was designed to support the hypothesis that networking agents binding to ubiquitous accessible targets in metastatic hormone-refractory prostate [...]]]></description>
		<wfw:commentRss>http://www.psa-rising.com/blog/2007/06/complete-remission-in-hormone-refractory-prostate-cancer/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Cougar&#8217;s CB7630 (abiraterone acetate) trial results</title>
		<link>http://www.psa-rising.com/blog/2007/05/cougars-cb7630-abiraterone-acetate-trial-results/</link>
		<comments>http://www.psa-rising.com/blog/2007/05/cougars-cb7630-abiraterone-acetate-trial-results/#comments</comments>
		<pubDate>Thu, 31 May 2007 14:44:51 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[CB7630 (abiraterone acetate)-Cougar]]></category>
		<category><![CDATA[Clinical trials]]></category>
		<category><![CDATA[Hormonal-ADT]]></category>
		<category><![CDATA[Hormone refractory]]></category>
		<category><![CDATA[Prostate Cancer]]></category>

		<guid isPermaLink="false">http://psa-rising.com/blog/index.php/2007/05/31/cougars-cb7630-abiraterone-acetate-trial-results</guid>
		<description><![CDATA[Cougar Biotechnology&#8217;s once-daily oral drug CB7630 (abiraterone acetate), based on recently announced trial results, appears o have some efficacy at two stages of the standard treatment path for androgen independent prostate cancer  &#8212; either before or after  chemotherapy. 
A UK Phase I/II trial of CB7630 reports positive signs among a small number of [...]]]></description>
		<wfw:commentRss>http://www.psa-rising.com/blog/2007/05/cougars-cb7630-abiraterone-acetate-trial-results/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
